Sandman L, Davidson M, Krugman S
Department of Pediatrics, New York University School of Medicine, New York 10016.
J Infect Dis. 1995 Mar;171 Suppl 1:S50-2. doi: 10.1093/infdis/171.supplement_1.s50.
The safety and immunogenicity of an inactivated hepatitis A vaccine (HM175) were evaluated in 151 seronegative health professionals (age range, 21-65 years; mean, 30). A 720-ELISA unit dose was administered to 78 vaccinees at 0, 1, and 6 months and to 73 vaccinees at 0, 1, and 12 months. Seroconversion rates were 90% in both groups 1 month after the first inoculation and 99% and 100%, respectively, 1 month after the second inoculation. Geometric mean antibody titers (GMTs) 1 month after the third inoculation were highest in the group vaccinated at 0, 1, and 12 months. GMTs were higher in women than in men. The vaccine was well tolerated; the most frequent side effect was transient soreness at the site of inoculation. No serious adverse reactions were observed. Thus, HM175 inactivated hepatitis A vaccine is safe and highly immunogenic.
在151名血清学阴性的卫生专业人员（年龄范围21 - 65岁，平均30岁）中评估了一种甲型肝炎灭活疫苗（HM175）的安全性和免疫原性。78名接种者在0、1和6个月时接种720 ELISA单位剂量疫苗，73名接种者在0、1和12个月时接种该剂量疫苗。两组在首次接种后1个月的血清转化率均为90%，第二次接种后1个月的血清转化率分别为99%和100%。在0、1和12个月接种疫苗的组中，第三次接种后1个月的几何平均抗体滴度（GMT）最高。女性的GMT高于男性。该疫苗耐受性良好；最常见的副作用是接种部位短暂疼痛。未观察到严重不良反应。因此，HM175甲型肝炎灭活疫苗安全且具有高度免疫原性。
